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Background: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of 
death and loss of disability-adjusted life-years. However, many COPD patients are not diagnosed 
because of underrecognition or underdiagnosis of this disease among many patients and physi-
cians. One possible reason is underrecognition of spirometry. In this study, we examined the 
prevalence of airflow limitation and underlying disease in patients with airflow limitation.
Methodology: From April 2006 to March 2008, patients who had spirometry performed 
were examined. The original disease of patients, pulmonary function tests, smoking status, and 
respiratory symptoms were surveyed from their medical records.
Results: Of all patients who had spirometry performed, 15.8% showed airflow limitation (FEV1/
FVC , 0.7). A variety of diseases were observed in patients with airflow limitation. Among all 
diseases, cardiovascular disease was the highest and gastrointestinal malignant disease had the 
second highest prevalence in patients with airflow limitation.
Conclusion: COPD might be frequent in conditions of comorbidity in patients treated for 
various diseases. Attention should be paid to the possibility of co-existence of COPD and the 
influence of COPD on these patients.
Keywords: airflow limitation, chronic obstructive pulmonary disease, comorbidity,   spirometry, 
prevalence
Introduction
The prevalence of chronic obstructive pulmonary disease (COPD) is about 10% 
worldwide.1,2 COPD was the fourth leading cause of death3 and will become the third 
leading cause of death by 2020.4 The Nippon COPD Epidemiology (NICE) study showed 
that the prevalence of airflow limitation was 8.6% in Japan.5 Although there are about 
5.3   million COPD patients in Japan estimated from this prevalence, only 220,000 patients 
are actually treated for COPD in primary care and hospitals. The discrepancy between the 
estimate in the NICE study and actual COPD patients is derived from underdiagnosis of 
COPD among physicians and underrecognition of COPD among patients. Furthermore, 
spirometry is not commonly used in primary care clinics.6 In primary care settings, the 
prevalence of COPD diagnosed by spirometry is 9.3% in Poland,7 4.6% in the UK,8 and 
10.3% in Japan.9 However, even with spirometry used in a general setting for screen-
ing of COPD, 63.2% of patients who had airflow limitation were not diagnosed with 
COPD.8 Therefore, underrecognition of COPD among general physicians might be one 
of the bigger problems for accurate diagnosis of COPD.
In general hospital settings, spirometry is usually performed in patients with 
nonrespiratory diseases. Minakata et al reported that the prevalence of COPD was International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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10.2% in nonrespiratory diseases and its prevalence was 
higher in patients with liver diseases,9 whereas the patients 
who undergo operations using general anesthesia are likely 
to have spirometry performed. A variety of diseases which 
are closely connected to cigarette smoking are involved in 
these cases, such as esophageal cancer, laryngeal cancer, 
lung cancer, and bladder cancer. However, the prevalence of 
COPD patients in university hospitals who have spirometry 
performed for nonrespiratory diseases has not been well 
studied. Furthermore, it is not well known which diseases 
are commonly observed among patients with COPD.10 Since 
Tottori University Hospital is one of the largest core hos-
pitals in our area, we carried out this study to investigate: 
1) the prevalence of airflow limitation in patients who had 
spirometry performed; and 2) the underlying diseases in 
patients who had airflow limitation in a university hospital 
setting.
Methodology
Data collection
From April 2006 to March 2008, patients who had   spirometry 
performed were analyzed using their medical records at 
  Tottori University Hospital. Spirometry was performed with a 
Chestac 33 spirometer (Chest Co, Tokyo, Japan). All patients 
were asked to perform a forced vital capacity (FVC) test at 
least three times and the highest FVC and forced expiratory 
volume in one second (FEV1) values were recorded. The 
medical records were reviewed to collect the following data: 
age, gender, FVC, FEV1, the original diseases, smoking sta-
tus, and respiratory symptoms such as dyspnea on exertion, 
cough, and sputum.
In this study, patients who were diagnosed with COPD 
as a primary disease, bronchial asthma, old pulmonary 
  tuberculosis, or congestive heart failure were excluded from 
the analysis. Patients who had had thoracic surgery were also 
excluded from the analysis. Airflow limitation was defined as 
FEV1/FVC (%FEV1) , 0.7 (70%). This study was approved 
by the local institutional review board.
stages of COPD
The severity of airflow limitation was classified according 
to GOLD (Global Initiative for Chronic Obstructive Lung 
Diseases)11 criteria as follows:
Stage I: Mild COPD characterized by mild airflow limita-
tion (FEV1/FVC , 0.70; %FEV1 $ 80%);
Stage II: Moderate COPD characterized by wors-
ening airflow limitation (FEV1/FVC , 0.70; 50% #  
%FEV1 , 80%);
Stage III: Severe COPD characterized by further wors-
ening of airflow limitation (FEV1/FVC , 0.70; 30% #  
%FEV1 , 50%);
Stage IV: Very severe COPD characterized by severe 
airflow limitation (FEV1/FVC , 0.70; %FEV1 , 30%).
statistical analysis
All data are expressed as mean ± standard deviation. The 
Mann–Whitney U-test or chi-square test was used to analyze 
the difference between data from the group with airflow limi-
tation and data from the group without airflow limitation. All 
statistical analysis was performed using Graph-Pad Prism 4.0 
(GraphPad Software Inc., San Diego, CA). Differences were 
considered to be statistically significant at P , 0.05.
Results
Characteristics of the patients
A total of 3,855 cases were analyzed. The average age, 
  gender, and smoking status are shown in Table 1. The   average 
age of all patients was 65.7 years. Females accounted for 
Table 1 Patient characteristics
All Patients with 
airflow limitation 
(%FEV1 , 70%)
Patients without 
airflow limitation 
(%FEV1 $ 70%)
number of patients (%) 3855 608 (15.8%) 3247 (84.2%)
Age (years) 65.7 ± 12.0 72.3 ± 8.61 63.4 ± 12.0*
gender (%) Male 1968 (51.1%) 462 (76.0%) 1506 (46.4%)**
Female 1887 (48.9%) 146 (24.0%) 1742 (53.6%)
smoking status (%) Current smoker 1571 (40.8%) 357 (58.7%) 1214 (37.4%)***
ex smoker 221 (5.7%) 114 (18.8%) 107 (3.3%)***
nonsmoker 2063 (53.5%) 137 (22.5%) 1926 (59.3%)
Notes: * = significantly different to the age of the patients with airflow limitation (P , 0.001); ** = significantly different compared to the percentage of males among patients 
with airflow limitation (P , 0.01); *** = significantly different compared to the percentages of current and past smokers among patients with airflow limitation (P , 0.01).
Abbreviation: %FeV1, ratio of forced expiratory volume in one second to forced vital capacity.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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48.9% of patients. Among all patients, 40.8% were current 
smokers; 5.7% were ex smokers, 53.5% were nonsmokers. 
Among all patients, 608 (15.8%) patients showed airflow 
limitation (FEV1/FVC , 0.7). Table 1 summarizes char-
acteristics of the subgroups of patients divided according 
to the presence of airflow limitation. The average age, the 
percentage of male, and the percentage of current or past 
smokers was significantly higher in patients with airflow 
limitation (Table 1).
The severity of airflow limitation was classified accord-
ing to GOLD criteria.11 The percentage of patients with mild 
airflow limitation (%FEV1 $ 80%) was 72%; the percentage 
with moderate airflow limitation (50% # %FEV1 , 80%) 
was 25.5%; the percentage with severe airflow limitation 
(30% # %FEV1 , 50%) was 2.5%; and the percentage 
with very severe airflow limitation (%FEV1 , 30%) was 
0.2% (Table 2).
We next asked whether patients experienced respiratory 
symptoms (Table 3). In patients with airflow limitation, 
259 patients (42.3%) experienced at least one respiratory 
symptom, such as dyspnea on exertion, cough, or sputum. 
Eighty-eight patients (14.3%) experienced dyspnea on 
exertion, 144 patients (23.5%) experienced cough, and 155 
patients (25.3%) experienced sputum. However, 353 patients 
(57.7%) experienced no respiratory symptoms.
We next examined the original diseases in patients with 
airflow limitation. In all, 289 patients (47.8%) had malig-
nant diseases and 319 patients (52.8%) had benign diseases 
(Tables 4 and 5). Among patients with malignant disease, the 
percentage of patients with gastrointestinal malignancy was 
highest (71 cases; 10.5%), the percentage of otolaryngeal, 
head, and neck cancer was the second highest (64 cases; 
10.5%), and the percentage of lung and mediastinal malig-
nancy was the third highest (53 cases; 8.7%) (Table 4). 
Among patients with benign tumor, the most frequent preva-
lent diseases were cardiovascular diseases (72 cases; 11.8%). 
The second most frequent diseases were orthopedic diseases 
(66 cases; 10.9%) and the third most frequent diseases were 
otolaryngeal diseases (60 cases; 9.9%) (Table 5).
Discussion
Prevalence of airflow limitation
In this study, we investigated the prevalence of patients with 
airway limitation among patients who had had spirometry 
performed. We showed that 15.8% of patients had airflow 
limitation. In primary care settings, the prevalence of airflow 
limitation was 11.4% in Japan9 and 9.3% in Poland.7 In 
these three studies, the prevalence of patients with airflow 
limitation was studied with a post-bronchodilator. The 
authors reported that airflow limitation was demonstrated 
in 15% of patients without a bronchodilator and in 11% 
with a bronchodilator.7 Therefore, our study might over-
estimate the prevalence of patients with airflow limitation. 
Furthermore, the patients’ background might influence 
the prevalence of patients with airflow limitation. In the 
NICE,5 PLATINO,2 and BOLD (Burden of Lung Disease)1 
studies, healthy people were surveyed for the prevalence of 
COPD.2,5,7 In primary care clinic settings, the participants 
suffered from some diseases, such as hypertension, diabe-
tes mellitus, hyperlipemia, or liver disease.9 In our study, 
patients had some comorbidity (Tables 4 and 5), and in 
Table 2 Breakdown of patients by severity of airflow limitation
stage I 80 # %FeV1 437 (71.9%)
stage II 50 # %FeV1 , 80 155 (25.5%)
stage III 30 # %FeV1 , 50 15 (2.5%)
stage IV 30 . %FeV1 1 (0.2%)
Total 608 (100%)
Abbreviation: %FeV1, ratio of forced expiratory volume in one second to forced 
vital capacity.
Table 3 Symptoms of patients with airflow limitation
no respiratory symptoms 351 (57.7%)
some respiratory symptoms 257 (42.3%)
Dyspnea on exertion 88 (14.3%)
Cough 144 (23.5%)
sputum 155 (25.3%)
Table 4 Comorbidity in patients with airflow limitation (benign 
disease)
Cardiovascular diseases (thoracic and abdominal aortic 
aneurysm, ischemic heart diseases, arteriosclerosis, etc)
72 (22.6%)
Orthopedic diseases (fractures, osteoarthritis, 
spondylosis, etc)
66 (20.1%)
Otolaryngeal diseases (chronic sinusitis, timpanitis, 
cyst of upper and lower jaw, etc)
60 (18.8%)
neurological diseases (brain infarction, Parkinson’s 
disease, depression, etc)
26 (8.9%)
Urologic diseases (benign prostatic hypertrophy, 
urinary stones, etc)
20 (6.3%)
gynecological diseases 15 (4.7%)
Dermatological diseases 13 (4.1%)
Inguinal and ventral hernia 11 (3.4%)
Liver and gall bladder diseases 9 (2.8%)
Ophthalmologic diseases 9 (2.8%)
Lung and mediastinal diseases 8 (2.5%)
Collagen vascular diseases 7 (2.2%)
gastrointestinal diseases 3 (0.9%)
Total 319 (100%)International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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many cases, spirometry was performed before an operation. 
Although the method of spirometry and the background 
of the patients affect the prevalence of airflow limitation, 
substantial numbers of patients with potent COPD might 
be underdiagnosed in university hospitals.
Comorbidities of COPD
Comorbidities of COPD affect symptoms and mortality 
of patients with COPD. Mapel et al reported that COPD 
patients were more likely to be admitted to the hospital and 
had a longer average length of stay than patients without 
COPD.12 They also reported that COPD patients had a 
higher prevalence of smoking-related comorbidities, such 
as heart disease, cancer, neurologic injuries, and gastritis. 
In this study, we surveyed which diseases are underlying in 
patients with airflow   limitation. There were many diseases 
which had possible COPD as comorbidity and most diseases 
were smoking-related.
Cardiovascular disease had the highest prevalence and 
malignant disease of the gastrointestinal area had the sec-
ond highest prevalence in this study. Soriano et al reported 
that COPD patients were at increased risk of pneumonia, 
osteoporosis, respiratory infection, myocardial infarction, 
angina, fracture, and glaucoma.10 On the other hand, an 
epidemiological study showed that the leading causes of 
smoking-attributed deaths were cancer, ischemic heart 
diseases, stroke, COPD, and pneumonia.13 Among the 
tobacco-related cancer sites, the lung, cervix uteri, lip/oral 
cavity, esophagus, urinary tract, pancreas, and stomach 
exhibited a high hazard ratio compared with nonsmokers. 
Among cardiovascular diseases (ischemic heart diseases, 
aortic aneurysm, and dissection), abdominal aortic aneurysm 
exhibited a high hazard ratio compared with nonsmokers.13 
Furthermore, Young et al reported that COPD is an important 
independent risk factor in lung cancer.14 Therefore, smoking-
related diseases such as cancer and cardiovascular diseases 
are closely related to COPD. While Minakata et al reported 
that the prevalence of COPD was different among the back-
ground diseases and patients with liver disease had high 
prevalence of COPD in a primary care setting,9 in our study, 
we did not check pre- and/or post-bronchodilator spirometry 
in each underlying disease. It is therefore a limitation of 
this study that we could not calculate precise prevalence of 
COPD in each underlying disease in all the patients in our 
hospital. However, COPD might be an underlying disease 
with high prevalence, especially among patients who have 
smoking-related diseases.
respiratory symptoms of the patients
In this study, we asked the patients with airflow limitation 
whether they had respiratory symptoms such as cough, 
sputum, and dyspnea on exertion. Yawn et al reported that 
evaluation of spirometry in patients with smoking history 
and chronic bronchitis symptoms might help for   diagnosis 
of COPD patients in general practice.15 Since the use 
of   spirometry are not practical in primary care settings, 
Price et al showed the usefulness of a symptoms-based 
questionnaire to detect COPD in patients with a smoking 
history.16,17 However, Akamatsu et al reported that symp-
toms such as dyspnea on exertion, cough, and sputum 
are less sensitive in detecting early COPD.18 In our study, 
57.7% of patients with airflow limitation had no respira-
tory symptoms. Therefore, spirometry should be used to 
identify COPD, even though patients have no respiratory 
symptoms.
Conclusion
In conclusion, a high prevalence of patients with airflow 
limitation was observed in a university hospital setting. 
Recent studies have shown that earlier trial of long-acting 
muscarinic antagonist has beneficial effects for patients 
with moderate to severe COPD, such as reductions in exac-
erbations, hospitalizations, risk of all cause mortality, and 
cardiovascular mortality.19 Therefore, earlier diagnosis and 
treatment of COPD as comorbidity with other diseases might 
be important and beneficial, not only for COPD itself, but 
also for patients’ original diseases to reduce mortality. Further 
study is needed to find the precise prevalence of COPD in 
smoking-related diseases and the influence of COPD on the 
underlying diseases.
Table 5 Comorbidity in patients with airflow limitation (malignant 
disease)
gastrointestinal diseases (gastric cancer, esophageal 
cancer, colon cancer, etc)
71 (24.6%)
Otolaryngeal, head and neck diseases (laryngeal 
or pharyngeal cancer, thyroid cancer)
64 (22.1%)
Lung and mediastinal diseases (lung cancer, 
thymoma, etc)
53 (18.3%)
Urological diseases (bladder cancer, renal pelvic 
cancer, etc)
42 (14.5%)
Dermatologic diseases (basal cell carcinoma, malignant 
melanoma, etc)
17 (5.9%)
hepatocellular and cholangiocellular carcinoma 14 (4.8%)
Breast cancer 11 (3.8%)
hematological malignancy 8 (2.8%)
gynecological malignancy 6 (2.1%)
Pancreas cancer 3 (1.0%)
Total 289 (100%)International Journal of COPD
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